-
Infection and Drug Resistance
- About Dovepress
Open access peer-reviewed scientific and medical journals.
- Open Access
Dove Medical Press is now a member of the Open Access Initiative
- An Author's Guide
A guide to help authors get their paper published.
- Advocacy
Support Open Access and Dove Press
- Reprints
Promotional Article Monitoring - further details
- Favored Author Program
Real benefits for authors, including fast-track processing of papers.
Current management options for latent tuberculosis: a review
Review
(4072) Total Article Views
Authors: Norton BL, Holland DP
Published Date November 2012 Volume 2012:5 Pages 163 - 173
DOI: http://dx.doi.org/10.2147/IDR.S29180
Received: | 29 August 2012 |
---|---|
Accepted: | 01 October 2012 |
Published: | 29 November 2012 |
Department of Medicine, Division of Infectious Diseases, Duke University Medical Center, Durham, NC, USA
Abstract: Tuberculosis remains the world’s second leading infectious cause of death, with nearly one-third of the global population latently infected. Treatment of latent tuberculosis infection is a mainstay of tuberculosis-control efforts in low-to medium-incidence countries. Isoniazid monotherapy has been the standard of care for decades, but its utility is impaired by poor completion rates. However, new, shorter-course regimens using rifamycins improve completion rates and are cost-saving compared with standard isoniazid monotherapy. We review the currently available therapies for latent tuberculosis infection and their toxicities and include a brief economic comparison of the different regimens.
Keywords: isoniazid, rifampin, rifapentine, tuberculin skin test, interferon-gamma release assay
Post to:
Cannotea Citeulike Del.icio.us Facebook LinkedIn Twitter
Readers of this article also read:
- Testimonials
"I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University.
- Evaluation of in-vitro antibiotic susceptibility of different morphological forms of Borrelia burgdorferi
- Subset-directed antiviral treatment of 142 herpesvirus patients with chronic fatigue syndrome
- Treatment of drug-resistant tuberculosis
- Lyme disease: the next decade